Company Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.
The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors.
In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants.
Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON).
The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630.
Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Country | United States |
| IPO Date | Feb 13, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 490 |
| CEO | Dr. Mark A. Goldsmith Ph.D. |
Contact Details
Address: 700 Saginaw Drive Redwood City, California United States | |
| Website | https://www.revmed.com |
Stock Details
| Ticker Symbol | RVMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001628171 |
| CUSIP Number | 76155X100 |
| ISIN Number | US76155X1000 |
| Employer ID | 47-2029180 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Goldsmith Ph.D. | Chief Executive Officer, President & Chairman |
| Jack Anders | Chief Financial Officer |
| Margaret A. Horn J.D. | Chief Operating Officer |
| Walter Reiher Ph.D. | Chief Information Officer |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research & Development |
| Jan Smith Ph.D. | Chief Scientific Officer |
| Xiaolin Wang | Executive Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 05, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 424B5 | Filing |
| Dec 04, 2024 | FWP | Filing |